Novasep Announces the Success of Its Consent Solicitation Extending the Maturity of Its Notes

Lyon, France (ots/PRNewswire) -

- All resolutions were approved by 100% of the participating
Noteholders and C Warrantholders
- Noteholders representing 99.9% of total outstanding principal
amount participated

Novasep Holding S.A.S ("Novasep"), a leading supplier of services
and technologies for the life sciences industry, is pleased to
announce that the consent solicitation that was launched on January
31, 2019 (the "Consent Solicitation") has achieved a successful
outcome.

The Consent Solicitation was launched in order to, inter alia:

A. extend the maturity of the senior notes in an initial
aggregate principal amount of EUR181,718,112 due May 31, 2019 issued
on November 3, 2016 by Novasep (ISIN: FR0013213568, Common Code
151496652) (the "Notes") to May 31, 2022 (the "Notes Maturity
Extension"),

B. extend the maturity of the C warrants expiring on May 31,
2019 issued by Novasep on November 3, 2016 (ISIN FR0013213576, Common
Code 151497047) (the "C Warrants") to May 31, 2022 (the "C Warrants
Maturity Extension"),

C. approve the waiver of certain conditions of the terms and
conditions of the Notes, amend certain terms and conditions of the
Notes and C Warrants and appoint DIIS Group as new representative
("Représentant de la masse") of the holders of Notes (the
"Noteholders") and of the holders of C Warrants (the "C
Warrantholders") all as detailed in a consent solicitation memorandum
dated January 31, 2019 prepared by Novasep in connection with the
Consent Solicitation (the "Consent Solicitation Memorandum").

The general meetings of the Noteholders and of the C
Warrantholders held on February 19, 2019 approved all of the
foregoing.

Michel Spagnol, Novasep's CEO and Chairman, said:

"I am delighted that our shareholders and bondholders have
confirmed their confidence in Novasep and its Rise-2 growth strategy.
We currently observe very good dynamics in most of our main markets
and notably in the biologics segment, which is an area of key focus
for Novasep. In addition, five of our key customer's products
(small-molecules) were successively approved by the FDA in 2018,
ensuring a significant growth driver for Novasep."

The Consent Solicitation Memorandum and all related documentation
are available upon request (i) at the registered office of Novasep,
(ii) at the specified office of Société Générale, acting as
centralizing agent, 32, rue du Champ de Tir CS 30812 44308 Nantes
Cedex 3 France (Phone + 33 2 51 85 65 93 -
agobligataire.fr@socgen.com) and (iii) on Novasep's website
(www.novasep.com) in the Investors section.

About Novasep

Novasep is a global provider of cost-effective and sustainable
manufacturing solutions for life sciences molecules and fine
chemicals. Novasep's unique offering includes process development
services, purification equipment and turnkey processes, contract
manufacturing services and complex active molecules to serve
pharmaceutical, biopharmaceutical, fine chemical, food and functional
ingredients as well as fermentation and chemical commodities
industries.

http://www.novasep.com

Disclaimer

This press release is not an offer of securities for sale or a
solicitation of an offer to purchase securities in the United States
or any other jurisdiction. The securities referred to herein have not
been and will not be registered under the US Securities Act of 1933,
as amended (the "Securities Act"), and may not be offered and sold in
the United States absent registration or an applicable exemption from
the registration requirements of the Securities Act.

The distribution of this press release in certain jurisdictions
may be restricted by law.

Logo: https://mma.prnewswire.com/media/815661/Novasep_Logo.jpg

Investor Contact:
Laure Saloin
Communication Project Manager - Corporate Branding & Social Media
laure.saloin@novasep.com
+33-(0)7-77-94-37-52

ots Originaltext: Novasep
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novasep, übermittelt durch news aktuell